EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective

Azik Hoffman, Gilad E Amiel

Cancers · 29.06.2023 · 15 (13) · 3402

DOI: 10.3390/cancers15133402 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.06.2023. Verfasst von Azik Hoffman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Rambam Health Care Center, Haifa 3109601, Israel. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) PET use in prostate cancer treatment has recently become a routinely used imaging modality by urologists. New, established data regarding its performance in different stages of prostate cancer, as well as gaining clinical knowledge with new tracers, drives the need for urologists and other clinicians to improve the utilization of this tool. While the use of PSMA PET/CT is more common in metastatic disease, in which it outperforms classical imaging modalities and drives treatment decisions and adjustments, recently, it gained ground in localized prostate cancer as well, especially in high-risk disease. Still, PSMA PET/CT might reveal lesions within the prostate or possibly locoregional or metastatic disease, not always representing true cancer when utilized in earlier stages of the disease, potentially adding diagnostic burden and changing treatment decisions. As urological treatment options advance toward focal treatments in localized organ-confined prostate cancer, recent reports suggest the utilization of PSMA PET/CT in treatment planning and follow-up and even when choosing active surveillance. This review aims to reveal the current perspective of urologists regarding its daily use.

Schlagwörter

Stichwörter der Autor:innen

PET CTPSMAprostate cancer

Autor:innen und Institutionen

  • Department of Urology, Rambam Health Care Center, Haifa 3109601, Israel.

Zitieren

APA

Hoffman, A., & Amiel, G. E. (2023). The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective. Cancers, 15(13), 3402. https://doi.org/10.3390/cancers15133402

Vancouver

Hoffman A, Amiel GE. The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective. Cancers. 2023;15(13):3402. doi:10.3390/cancers15133402

BibTeX
@article{Hoffman2023,
  author = {Hoffman, Azik and Amiel, Gilad E},
  title = {The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {13},
  pages = {3402},
  doi = {10.3390/cancers15133402}
}
Kostenlos starten →